ICAD (iCAD Corp) Forward P/E Multiple

Official company branding of iCAD (ICAD)

iCAD, Inc. is implementing eco-friendly AI solutions for oncology diagnostics, eliminating paper-based records from medicine. The company's cloud technologies accelerate data transmission, optimizing clinical logistics. Growth in subscription software effectively balances the hardware segment of the business. This forward P/E chart illustrates the asset's valuation dynamics, where 0.00 determines the current status of the parameter.

icadmed.com - ICAD Forward P/E Multiple (period 07/04/2022 - 08/02/2025)

Summary analytical data breakdowns for iCAD Corp (ICAD)

- current price and projected stock value:
Stock Quotes iCAD, Inc.|ICAD - Fair Value Consensus
- business market valuation indicators:
Market Capitalization iCAD Inc.|ICAD - Real Price to Acquire Entire Company
- book capitalization information:
Accounting Value per Share iCAD|ICAD - Book Capitalization|Market Value to Book Value Ratio icadmed.com|ICAD - Aggregate Asset Value
- issuer credit burden and liquidity indicators:
Total Debt to Capital iCAD, Inc.|ICAD - Long-Term Liabilities to Capital|Short-Term Debt to Capital iCAD, Inc.|ICAD - Company Total Debt Obligations|Debts to Book Capitalization iCAD Inc.|ICAD - Company Long-Term Liabilities|Company Short-Term Debts iCAD|Quick Ratio icadmed.com
- financial results and valuation multiples details:
ICAD - Company Profit|Future Profit iCAD, Inc.|ICAD - Company Value to Net Income|Forward P/E Multiple iCAD, Inc.|ICAD - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iCAD Inc.|ICAD - Operating profit before amortization|Net earnings per share (EPS TTM) iCAD|ICAD - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months icadmed.com|ICAD - Expected net earnings per share growth this year|Earnings growth forecast for next year iCAD, Inc.
Basic company analysis:iCAD
Brand item of iCAD Corp

Stable demand for medical innovations from iCAD, Inc. (ICAD) creates a defensive asset profile that remains independent of global macroeconomic fluctuations. Investors should evaluate the ratio of the current price to projected earnings, where the expected P/E multiple for iCAD, Inc. on GURU.Markets allows for determining the extent of overpayment for future cash flows and identifying risks of fundamental business overvaluation.

Competitors of iCAD, Inc.

Projected Price to Earnings ONC (BeiGene)|HALO (Halozyme Therapeutics, Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (RevMed)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Therapeutics (BCAX) - Future Price to Earnings|Personalis Inc - Future Price to Earnings Multiple|ERAS (Erasca Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Corp DCTH|Forward P/E Multiple YMAB|Market Cap to Projected Earnings aurabiosciences.com|Forward P/E Multiple CADL (Candel Therapeutics, Inc.)|ARAY - Projected Price to Earnings|SELLAS Life Sciences Group Inc. - Forward P/E Multiple|ACTU - Forward P/E Multiple|CTOR: Forward P/E Multiple|Price to Future Earnings Ratio HURA|Projected Price to Earnings TARA|FATE: Future Price to Earnings Multiple|Forward P/E Multiple WHWK|Market Cap to Projected Earnings tscan.com|Future Price to Earnings Champions Oncology, Inc. CSBR|XBIT: Price to Future Earnings Ratio|CEL-SCI Corp - Forward P/E Multiple|OS Therapies Inc. (OSTX) - Projected Price to Earnings|RADX (Radiopharm Theranostics Limited) - Projected Price to Earnings|ARTV - Market Cap to Projected Earnings|ANL (Adlai Nortye Ltd) - Forward P/E Multiple|verupharma.com (VERU) - Market Cap to Projected Earnings|Forward P/E Multiple TPST|Projected Price to Earnings xiliotx.com XLO|Forward P/E Multiple RENB (Renovaro)|Forward P/E Multiple Mural Oncology PLC MURA|Kairos Pharma Inc - Forward P/E Multiple|OKUR (OnKure Therapeutics Inc) - Price to Future Earnings Ratio|GDTC: Forward P/E Multiple|Projected Price to Earnings Curis|APLM (Apollomics Inc.) - Forward P/E Multiple|Forward P/E Multiple Tharimmune Corporation|Future Price to Earnings Advanced Biomed Inc (ADVB)|genprex.com - Price to Future Earnings Ratio|Forward P/E Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Projected Price to Earnings|Xenetic Bio - Forward P/E Multiple|Projected Price to Earnings Ratio Salarius Pharma|Purple Biotech (PPBT) - Future Price to Earnings|American Oncology Network, Inc. - Future Price to Earnings Multiple|Projected Price to Earnings BGNE|CKPT: Future Price to Earnings Multiple|Forward P/E Multiple ELEV|Projected Price to Earnings ikenaoncology.com IKNA|Notable Labs, Ltd. - Projected Price to Earnings|Forward P/E Multiple Viracta Therapeutics Inc. VIRX|MOR - Future Price to Earnings|Future Price to Earnings Multiple NAYA (NAYA Biosciences Inc)|AAPGV: Forward P/E Multiple